Ujvira 160mg Injection is a targeted therapy containing the active constituent trastuzumab emtansine. It is used to treat adults with a type of breast cancer (human epidermal growth factor receptor 2 positive breast cancer) that has spread to other parts of the body or has not improved after treatment with other medications. It is a combination of two drugs: trastuzumab, which is a monoclonal antibody that targets HER2-positive breast cancer cells, and emtansine, which is a chemotherapy drug that destroys cancer cells. This medicine is also given after surgery to kill any cancer cells left in the breast (adjuvant therapy). This medication is not recommended for adolescents and children under 18. Before taking this medicine, it is vital to inform your doctor if you have any blood clot disorders, liver disorders, or allergies.

Breast cancer (human epidermal growth factor receptor 2 positive breast cancer).

Trastuzumab binds selectively to the HER2 receptors on breast cancer cells' surface, blocks them from receiving growth signals, and stops the cancer cell's growth. DM1 becomes active once the drug enters the cancer cells and helps stop cancer cell growth.

• Ujvira 160mg Injection shall either be administered before or after surgery.
• It will be given as an Intravenous infusion for 90 minutes, if well tolerated it shall be administered within 30 minutes for the next doses.

Serious:

Heart Problems

Allergic reactions

Kidney problems

Breathing difficulties

Common:

Fever

Visual disturbances

Nose bleeds or runny nose

Hair loss

Dizziness

Nail disorders

Weight loss

Loss of appetite

Bruising

Dry mouth

Liver inflammation

Muscle pain

Asthma/ lung disorders

Inform your doctor about any prescribed medications, over-the-counter medicines, nutritional and vitamin supplements, and herbal products you take or have taken before the treatment. Certain medications may interact with Ujvira 160mg Injection and cause undesirable side effects.

• Store between 2˚C and 8˚C.
• Keep Ujvira 160mg Injection out of sight and reach of children.

It is suggested to inform your doctor if you have a history of allergic reactions to Ujvira 160mg Injections to avoid life-threatening complications. If you have a history of lung disorder or breathing problems, inform your doctor before the treatment commencement. Avoid planning for pregnancy and breastfeeding for a minimum of 7 months after the last dose. Monitor your heart parameters regularly during the treatment with Ujvira 160mg Injection as it may impact the functioning of the heart. Always maintain a healthy and balanced diet to support your overall health and well-being.